Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?

Eli Lilly’s (LLY) top-line growth in the second quarter is expected to have been driven by strong demand for its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. Tirzepatide is a dual GIP and GLP-1 receptor agonist. The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c and reducing cardiovascul ...